Cost-effectiveness of percutaneous coronary intervention in patients with stable coronary artery disease and abnormal fractional flow reserve

Circulation

Volumn 128, Issue 12, 2013, Pages 1335-1340

  Fearon, William F ^a   Shilane, David ^b   Pijls, Nico H J ^a,c   Boothroyd, Derek B ^b   Tonino, Pim A L ^a,c   Barbato, Emanuele ^d   Jüni, Peter ^e   De Bruyne, Bernard ^d   Hlatky, Mark A ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Health Research and Policy ^*  (United States)

^c CATHARINA HOSPITAL   (Netherlands)

^d CARDIOVASCULAR CENTER   (Belgium)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

coronary disease; fractional flow reserve, myocardial; percutaneous coronary intervention

Indexed keywords

ADENOSINE; ANTIANGINA PECTORIS AGENT; ANTITHROMBOCYTIC AGENT; GLYCOPROTEIN P INHIBITOR;

ADULT; ADVERSE OUTCOME; AGED; ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ARTICLE; BALLOON CATHETER; BARE METAL STENT; CARDIOPULMONARY EXERCISE TEST; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG ELUTING STENT; ECONOMIC EVALUATION; FEMALE; FOLLOW UP; FRACTIONAL FLOW RESERVE; GUIDE WIRE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SURVEY; HEART CATHETER; HEART CATHETERIZATION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION COST; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MEDICARE; OUTPATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; STABLE ANGINA PECTORIS;

CORONARY DISEASE; FRACTIONAL FLOW RESERVE, MYOCARDIAL; PERCUTANEOUS CORONARY INTERVENTION;

AGED; ANGINA, STABLE; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; FRACTIONAL FLOW RESERVE, MYOCARDIAL; HEALTH SURVEYS; HOSPITAL COSTS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 84884290482     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.003059     Document Type: Article

References (10)

1. Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, Bangalore S. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv. 2012;5:476-490.
2. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516.
3. Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, Maron DJ, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG; Department of Veterans Affairs Cooperative Studies Program No. 424 (COURAGE Trial) Investigators and Study Coordinators. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes. 2008;1:12-20.
4. Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, Maccarthy PA, Van't Veer M, Pijls NH. Angiographic versus functional severity of coronary artery stenoses in the FAME study: Fractional Flow Reserve Versus Angiography in Multivessel Evaluation. J Am Coll Cardiol. 2010;55:2816-2821.
5. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213-224.
6. Fearon WF, Bornschein B, Tonino PA, Gothe RM, Bruyne BD, Pijls NH, Siebert U; Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) Study Investigators. Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. Circulation. 2010;122:2545-2550.
7. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Möbius-Winkler S, Mobius-Winckler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Jüni P, Fearon WF; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991-1001.
8. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. N Engl J Med. 1997;336:92-99.
9. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203-220.
10. Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, Zhang W, Hartigan PM, Lewis C, Veledar E, Bowen J, Dunbar SB, Deaton C, Kaufman S, O'Rourke RA, Goeree R, Barnett PG, Teo KK, Boden WE, Mancini GB; COURAGE Trial Research Group. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359:677-687.